Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jüri Reimand is active.

Publication


Featured researches published by Jüri Reimand.


Nucleic Acids Research | 2011

g:Profiler—a web server for functional interpretation of gene lists (2011 update)

Jüri Reimand; Tambet Arak; Jaak Vilo

Functional interpretation of candidate gene lists is an essential task in modern biomedical research. Here, we present the 2011 update of g:Profiler (http://biit.cs.ut.ee/gprofiler/), a popular collection of web tools for functional analysis. g:GOSt and g:Cocoa combine comprehensive methods for interpreting gene lists, ordered lists and list collections in the context of biomedical ontologies, pathways, transcription factor and microRNA regulatory motifs and protein–protein interactions. Additional tools, namely the biomolecule ID mapping service (g:Convert), gene expression similarity searcher (g:Sorter) and gene homology searcher (g:Orth) provide numerous ways for further analysis and interpretation. In this update, we have implemented several features of interest to the community: (i) functional analysis of single nucleotide polymorphisms and other DNA polymorphisms is supported by chromosomal queries; (ii) network analysis identifies enriched protein–protein interaction modules in gene lists; (iii) functional analysis covers human disease genes; and (iv) improved statistics and filtering provide more concise results. g:Profiler is a regularly updated resource that is available for a wide range of species, including mammals, plants, fungi and insects.


Nucleic Acids Research | 2007

g:Profiler—a web-based toolset for functional profiling of gene lists from large-scale experiments

Jüri Reimand; Meelis Kull; Hedi Peterson; Jaanus Hansen; Jaak Vilo

g:Profiler (http://biit.cs.ut.ee/gprofiler/) is a public web server for characterising and manipulating gene lists resulting from mining high-throughput genomic data. g:Profiler has a simple, user-friendly web interface with powerful visualisation for capturing Gene Ontology (GO), pathway, or transcription factor binding site enrichments down to individual gene levels. Besides standard multiple testing corrections, a new improved method for estimating the true effect of multiple testing over complex structures like GO has been introduced. Interpreting ranked gene lists is supported from the same interface with very efficient algorithms. Such ordered lists may arise when studying the most significantly affected genes from high-throughput data or genes co-expressed with the query gene. Other important aspects of practical data analysis are supported by modules tightly integrated with g:Profiler. These are: g:Convert for converting between different database identifiers; g:Orth for finding orthologous genes from other species; and g:Sorter for searching a large body of public gene expression data for co-expression. g:Profiler supports 31 different species, and underlying data is updated regularly from sources like the Ensembl database. Bioinformatics communities wishing to integrate with g:Profiler can use alternative simple textual outputs.


Scientific Reports | 2013

Comprehensive identification of mutational cancer driver genes across 12 tumor types.

David Tamborero; Abel Gonzalez-Perez; Christian Perez-Llamas; Jordi Deu-Pons; Cyriac Kandoth; Jüri Reimand; Michael S. Lawrence; Gad Getz; Gary D. Bader; Li Ding; Nuria Lopez-Bigas

With the ability to fully sequence tumor genomes/exomes, the quest for cancer driver genes can now be undertaken in an unbiased manner. However, obtaining a complete catalog of cancer genes is difficult due to the heterogeneous molecular nature of the disease and the limitations of available computational methods. Here we show that the combination of complementary methods allows identifying a comprehensive and reliable list of cancer driver genes. We provide a list of 291 high-confidence cancer driver genes acting on 3,205 tumors from 12 different cancer types. Among those genes, some have not been previously identified as cancer drivers and 16 have clear preference to sustain mutations in one specific tumor type. The novel driver candidates complement our current picture of the emergence of these diseases. In summary, the catalog of driver genes and the methodology presented here open new avenues to better understand the mechanisms of tumorigenesis.


Nature Methods | 2015

Pathway and network analysis of cancer genomes

Pau Creixell; Jüri Reimand; Syed Haider; Guanming Wu; Tatsuhiro Shibata; Miguel Vazquez; Ville Mustonen; Abel Gonzalez-Perez; John V. Pearson; Chris Sander; Benjamin J. Raphael; Debora S. Marks; B. F. Francis Ouellette; Alfonso Valencia; Gary D. Bader; Paul C. Boutros; Joshua M. Stuart; Rune Linding; Nuria Lopez-Bigas; Lincoln Stein

Genomic information on tumors from 50 cancer types cataloged by the International Cancer Genome Consortium (ICGC) shows that only a few well-studied driver genes are frequently mutated, in contrast to many infrequently mutated genes that may also contribute to tumor biology. Hence there has been large interest in developing pathway and network analysis methods that group genes and illuminate the processes involved. We provide an overview of these analysis techniques and show where they guide mechanistic and translational investigations.


Nature Methods | 2013

Computational approaches to identify functional genetic variants in cancer genomes

Abel Gonzalez-Perez; Ville Mustonen; Boris Reva; Graham R. S. Ritchie; Pau Creixell; Rachel Karchin; Miguel Vazquez; J. Lynn Fink; Karin S. Kassahn; John V. Pearson; Gary D. Bader; Paul C. Boutros; Lakshmi Muthuswamy; B. F. Francis Ouellette; Jüri Reimand; Rune Linding; Tatsuhiro Shibata; Alfonso Valencia; Adam Butler; Serge Dronov; Paul Flicek; Nick B. Shannon; Hannah Carter; Li Ding; Chris Sander; Josh Stuart; Lincoln Stein; Nuria Lopez-Bigas

The International Cancer Genome Consortium (ICGC) aims to catalog genomic abnormalities in tumors from 50 different cancer types. Genome sequencing reveals hundreds to thousands of somatic mutations in each tumor but only a minority of these drive tumor progression. We present the result of discussions within the ICGC on how to address the challenge of identifying mutations that contribute to oncogenesis, tumor maintenance or response to therapy, and recommend computational techniques to annotate somatic variants and predict their impact on cancer phenotype.


Proceedings of the National Academy of Sciences of the United States of America | 2015

Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity

Mona Meyer; Jüri Reimand; Xiaoyang Lan; Renee Head; Xueming Zhu; Michelle Kushida; Jane Bayani; Jessica C. Pressey; Anath C. Lionel; Ian Clarke; Michael D. Cusimano; Jeremy A. Squire; Stephen W. Scherer; Mark Bernstein; Melanie A. Woodin; Gary D. Bader; Peter Dirks

Significance Glioblastoma is an incurable brain tumor. It is characterized by intratumoral phenotypic and genetic heterogeneity, but the functional significance of this heterogeneity is unclear. We devised an integrated functional and genomic strategy to obtain single cell-derived tumor clones directly from patient tumors to identify mechanisms of aggressive clone behavior and drug resistance. Genomic analysis of single clones identified genes associated with clonal phenotypes. We predict that integration of functional and genomic analysis at a clonal level will be essential for understanding evolution and therapeutic resistance of human cancer, and will lead to the discovery of novel driver mechanisms and clone-specific cancer treatment. Glioblastoma (GBM) is a cancer comprised of morphologically, genetically, and phenotypically diverse cells. However, an understanding of the functional significance of intratumoral heterogeneity is lacking. We devised a method to isolate and functionally profile tumorigenic clones from patient glioblastoma samples. Individual clones demonstrated unique proliferation and differentiation abilities. Importantly, naïve patient tumors included clones that were temozolomide resistant, indicating that resistance to conventional GBM therapy can preexist in untreated tumors at a clonal level. Further, candidate therapies for resistant clones were detected with clone-specific drug screening. Genomic analyses revealed genes and pathways that associate with specific functional behavior of single clones. Our results suggest that functional clonal profiling used to identify tumorigenic and drug-resistant tumor clones will lead to the discovery of new GBM clone-specific treatment strategies.


Scientific Reports | 2013

The mutational landscape of phosphorylation signaling in cancer

Jüri Reimand; Omar Wagih; Gary D. Bader

Somatic mutations in cancer genomes include drivers that provide selective advantages to tumor cells and passengers present due to genome instability. Discovery of pan-cancer drivers will help characterize biological systems important in multiple cancers and lead to development of better therapies. Driver genes are most often identified by their recurrent mutations across tumor samples. However, some mutations are more important for protein function than others. Thus considering the location of mutations with respect to functional protein sites can predict their mechanisms of action and improve the sensitivity of driver gene detection. Protein phosphorylation is a post-translational modification central to cancer biology and treatment, and frequently altered by driver mutations. Here we used our ActiveDriver method to analyze known phosphorylation sites mutated by single nucleotide variants (SNVs) in The Cancer Genome Atlas Research Network (TCGA) pan-cancer dataset of 3,185 genomes and 12 cancer types. Phosphorylation-related SNVs (pSNVs) occur in ~90% of tumors, show increased conservation and functional mutation impact compared to other protein-coding mutations, and are enriched in cancer genes and pathways. Gene-centric analysis found 150 known and candidate cancer genes with significant pSNV recurrence. Using a novel computational method, we predict that 29% of these mutations directly abolish phosphorylation or modify kinase target sites to rewire signaling pathways. This analysis shows that incorporation of information about protein signaling sites will improve computational pipelines for variant function prediction.


Cancer Cell | 2017

Intertumoral Heterogeneity within Medulloblastoma Subgroups

Florence M.G. Cavalli; Marc Remke; Ladislav Rampasek; John Peacock; David Shih; Betty Luu; Livia Garzia; Jonathon Torchia; Carolina Nör; A. Sorana Morrissy; Sameer Agnihotri; Yuan Yao Thompson; Claudia M. Kuzan-Fischer; Hamza Farooq; Keren Isaev; Craig Daniels; Byung Kyu Cho; Seung Ki Kim; Kyu Chang Wang; Ji Yeoun Lee; Wieslawa A. Grajkowska; Marta Perek-Polnik; Alexandre Vasiljevic; Cécile Faure-Conter; Anne Jouvet; Caterina Giannini; Amulya A. Nageswara Rao; Kay Ka Wai Li; Ho Keung Ng; Charles G. Eberhart

While molecular subgrouping has revolutionized medulloblastoma classification, the extent of heterogeneity within subgroups is unknown. Similarity network fusion (SNF) applied to genome-wide DNA methylation and gene expression data across 763 primary samples identifies very homogeneous clusters of patients, supporting the presence of medulloblastoma subtypes. After integration of somatic copy-number alterations, and clinical features specific to each cluster, we identify 12 different subtypes of medulloblastoma. Integrative analysis using SNF further delineates group 3 from group 4 medulloblastoma, which is not as readily apparent through analyses of individual data types. Two clear subtypes of infants with Sonic Hedgehog medulloblastoma with disparate outcomes and biology are identified. Medulloblastoma subtypes identified through integrative clustering have important implications for stratification of future clinical trials.


Genome Biology | 2009

Mining for coexpression across hundreds of datasets using novel rank aggregation and visualization methods

Priit Adler; Meelis Kull; Aleksandr Tkachenko; Hedi Peterson; Jüri Reimand; Jaak Vilo

We present a web resource MEM (Multi-Experiment Matrix) for gene expression similarity searches across many datasets. MEM features large collections of microarray datasets and utilizes rank aggregation to merge information from different datasets into a single global ordering with simultaneous statistical significance estimation. Unique features of MEM include automatic detection, characterization and visualization of datasets that includes the strongest coexpression patterns. MEM is freely available at http://biit.cs.ut.ee/mem/.


Nucleic Acids Research | 2008

GraphWeb: mining heterogeneous biological networks for gene modules with functional significance

Jüri Reimand; Laur Tooming; Hedi Peterson; Priit Adler; Jaak Vilo

Deciphering heterogeneous cellular networks with embedded modules is a great challenge of current systems biology. Experimental and computational studies construct complex networks of molecules that describe various aspects of the cell such as transcriptional regulation, protein interactions and metabolism. Groups of interacting genes and proteins reflect network modules that potentially share regulatory mechanisms and relate to common function. Here, we present GraphWeb, a public web server for biological network analysis and module discovery. GraphWeb provides methods to: (1) integrate heterogeneous and multispecies data for constructing directed and undirected, weighted and unweighted networks; (ii) discover network modules using a variety of algorithms and topological filters and (iii) interpret modules using functional knowledge of the Gene Ontology and pathways, as well as regulatory features such as binding motifs and microRNA targets. GraphWeb is designed to analyse individual or multiple merged networks, search for conserved features across multiple species, mine large biological networks for smaller modules, discover novel candidates and connections for known pathways and compare results of high-throughput datasets. The GraphWeb is available at http://biit.cs.ut.ee/graphweb/.

Collaboration


Dive into the Jüri Reimand's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

B. F. Francis Ouellette

Ontario Institute for Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Lina Wadi

Ontario Institute for Cancer Research

View shared research outputs
Researchain Logo
Decentralizing Knowledge